Cargando…
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer
BACKGROUND: Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology that has recently found its way into routine practice as an adjunct to tissue biopsy (TB). The concept of LB refers to any tumor-derived material, such as circulating tumor DNA (ctDNA) or circulating tumor ce...
Autores principales: | Heitzer, E., van den Broek, D., Denis, M.G., Hofman, P., Hubank, M., Mouliere, F., Paz-Ares, L., Schuuring, E., Sültmann, H., Vainer, G., Verstraaten, E., de Visser, L., Cortinovis, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867049/ https://www.ncbi.nlm.nih.gov/pubmed/35202954 http://dx.doi.org/10.1016/j.esmoop.2022.100399 |
Ejemplares similares
-
Refined characterization of circulating tumor DNA through biological feature integration
por: Markus, Havell, et al.
Publicado: (2022) -
The dynamic range of circulating tumor DNA in metastatic breast cancer
por: Heidary, Maryam, et al.
Publicado: (2014) -
Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020) -
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011) -
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2012)